Hormonal
Sarcopenia (low skeletal muscle mass) is independently associated with increased insulin resistance and dysglycemia, and this association is significantly stronger in individuals under 60 years of age compared to those 60 and older.
Maintaining or building skeletal muscle mass is a critical strategy for metabolic health, independent of your weight. This is especially important for adults under 60, where low muscle mass strongly predicts insulin resistance and diabetes risk. Focus on resistance training and adequate protein intake to preserve muscle, not just fat loss.
Sarcopenia was associated with insulin resistance in non-obese (HOMA IR ratio 1.39, 95% confidence interval (CI) 1.26 to 1.52) and obese individuals (HOMA-IR ratio 1.16, 95% CI 1.12 to 1.18). Sarcopenia was associated with dysglycemia in obese individuals (HbA1C ratio 1.021, 95% CI 1.011 to 1.043) but not in non-obese individuals. Associations were stronger in those under 60 years of age.
Why this rating
Large cross-sectional observational study (NHANES III, N=14,528) with rigorous statistical adjustment, but limited by cross-sectional design preventing causal inference.
Source
Sarcopenia Exacerbates Obesity-Associated Insulin Resistance and Dysglycemia: Findings from the National Health and Nutrition Examination Survey III
Preethi Srikanthan et al. · PLoS ONE · 2010
DOI 10.1371/journal.pone.0010805
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →